TIDMOPTI

RNS Number : 7603E

OptiBiotix Health PLC

09 July 2021

Opti B i otix Health plc

( ÒOpti Bi o t ixÓ or the ÒCompanyÓ)

Result of AGM

OptiBi otix Health p lc (AI M : OPTI), a life sciences busi ness d e vel o ping co m p o u n ds to tack le o besit y, high

choleste r ol, diabetes and skincare, a nnounces that at the Annual General Meeting (ÒAGMÓ) held earlier today, all resolutions were duly passed.

As shareholders were unable to attend the AGM in person as a result of the ongoing pandemic, they were given the option to submit questions in advance. These questions have been addressed and will be available to view on the website, along with the voting results, later today: https://www.optibiotix-ir.com/content/investors/shareholder-information

For further information, please contact:

 
 OptiBiotix Health plc                                   www.optibiotix.com 
 Neil Davidson, Chairman                         Contact via Walbrook below 
 Stephen O'Hara, Chief Executive 
 
 Cairn Financial Advisers LLP (NOMAD)                    Tel: 020 7213 0880 
 Liam Murray / Jo Turner / Ludovico Lazzaretti 
 
 Cenkos Securities plc (Broker)                          Tel: 020 7397 8900 
 Callum Davidson / Neil McDonald 
 Michael Johnson / Russell Kerr (Sales) 
 
 Walbrook PR Ltd                                         Mob: 07876 741 001 
 Anna Dunphy 
 
 
 
 
   About OptiBiotix - www.optibiotix.com 
   OptiBiotix Health plc (AIM: OPTI), which was formed in March 
   2012, brings science to the development of compounds which 
   modify the human microbiome Ð the collective genome 
   of the microbes in the body Ð in order to prevent and 
   manage human disease and promote wellness. 
   OptiBiotix has an extensive R&D programme working with leading 
   academics in the development of microbial strains, compounds, 
   and formulations which are used as active ingredients and 
   supplements. More than twenty international food and healthcare 
   supplement companies have signed agreements with OptiBiotix 
   to incorporate their human microbiome modulators into a 
   wide range of food products and drinks. 
   OptiBiotix is also developing its own range of consumer 
   supplements and health products. The CompanyÕs current 
   areas of focus include obesity, cardiovascular health, and 
   diabetes. 
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGRLMLTMTIMMPB

(END) Dow Jones Newswires

July 09, 2021 05:49 ET (09:49 GMT)

Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Sep 2021 to Oct 2021 Click Here for more Optibiotix Health Charts.
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Oct 2020 to Oct 2021 Click Here for more Optibiotix Health Charts.